Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Metastatic Hormone-Resistant Prostate Cancer
NCT00006023Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Mar 2000
- Primary completion
- Jun 2001
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in prostate cancer (PCa), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Prostate-Specific Antigen Response. Started Mar 2000; status: completed.
02
Drugs
capecitabine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00006023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006023.